In a German cohort of 581 breast cancer patients with a strong family history of breast/ovarian cancers, pathogenic variants in PALB2, TP53 and CDH1 were only found in 1%, 0.3% and 0% of the patients, respectively [29]. This evidence concerns the gene TP53 and ovarian carcinoma.